AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III study titled ‘A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)’. This study aims to evaluate the efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig alone compared to pembrolizumab monotherapy in treating advanced non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression.
The study is testing two main interventions: Datopotamab Deruxtecan (Dato-DXd) combined with Rilvegostomig, and Rilvegostomig monotherapy. These are compared against Pembrolizumab monotherapy, a standard treatment. The goal is to assess their effectiveness as first-line therapies for patients with high PD-L1 expression NSCLC.
This is an interventional study with a randomized, parallel assignment model. It is open-label, meaning both researchers and participants know which treatment is being administered, but outcomes assessors are blinded. The primary purpose is treatment-focused, aiming to determine the best first-line therapy option.
The study began on April 11, 2024, with its primary completion and estimated overall completion dates yet to be announced. The last update was submitted on July 25, 2025, indicating ongoing recruitment and progress.
For investors, this study could significantly impact AstraZeneca’s stock performance, especially if the results favor the new drug combinations over existing treatments like Pembrolizumab. Positive outcomes could enhance AstraZeneca’s competitive edge in the oncology market, particularly in the NSCLC segment.
The study is currently recruiting, with further details available on the ClinicalTrials portal.